US-based venture capital firm CD Ventures provides further $2m for Germany-based Noxxon Pharma.
Noxxon Pharma, a Germany-based drug developer focused on blood and inflammatory diseases, has raised an extra €2m in its series D round, having initially closed it in May at €33m ($46m).
The extra money came from US-based venture capital firm CD Ventures.
In May, Dow Venture Capital, the corporate venturing unit of US-based Dow Chemical Company, reinvested in Noxxon’s fourth round led by NGN Capital as a new investor. NGN’s VC and German state-backed peers, TVM Capital, Sofinnova Partners,…
